Exploring New Immunological Pathways and Patient-reported Outcomes That Can Improve the Care of Moderate to Severe Ulcerative Colitis: A Game On! Challenge

0.50 CME
$0 FEE
game on challenge


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by an educational grant from Genentech, Inc.

Activity Description

Although numerous therapies are available for the treatment of moderate to severe ulcerative colitis (UC), many patients still suffer poor quality of life and outcomes. Ulcerative colitis is a relapsing and remitting disease, with varied and changing incidence rates worldwide. It also has an unpredictable disease course and is associated with a high health economic burden. These and other findings underscore the importance of learning about new therapies that may reduce the treatment burden of UC care. The therapeutic landscape is continuing to evolve, and agents that target the immunological pathways of UC are of great interest to gastroenterologists and other health care professionals. This Game On! activity is an interactive quiz of knowledge and confidence in which participants answer questions, then select the level of confidence in their answers to achieve the highest score among their peers. The faculty of this program will explore investigational agents with unique mechanisms of action in late-stage development for the treatment of patients with moderate to severe UC as well as apply new clinical data on the efficacy and safety of therapeutic agents that target the immunological pathways of UC. Patient-reported outcomes measures that may improve the treatment of inflammatory bowel disease will also be examined in the game.

Target Audience

The intended audience for this activity is gastroenterologists, advanced practice providers and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objective

Upon successful completion of this activity, participants should be better able to:

  • Explore unique mechanisms of action and therapeutics that can improve the treatment of moderate to severe ulcerative colitis.
  • Apply new clinical findings on the efficacy and safety of therapeutics that target immunological pathways in the treatment of moderate to severe ulcerative colitis.
  • Examine patient-reported outcomes (PROs) measures that may improve the treatment of inflammatory bowel disease by providing expanded information about signs, symptoms, and functional disabilities.


Millie D. Long, MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 27, 2020, to October 26, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the poll and pretest questions, view the content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.

Faculty reports the following relationship(s)

Millie D. Long, MD, MPH
Consulting Fee: AbbVie, Janssen, Pfizer, Prometheus, Salix, Takeda, Target PharmaSolutions, UCB, Valeant

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose. 

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com